Lineage Cell Therapeutics, Inc.LCTXNYSE
Loading
Operating Expenses Over TimeStable
Percentile Rank36
3Y CAGR-0.9%
5Y CAGR+5.8%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-0.9%/yr
vs -3.5%/yr prior
5Y CAGR
+5.8%/yr
Recent deceleration
Acceleration
+2.6pp
Accelerating
Percentile
P36
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
1 yr
Consecutive growthStable
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $35.49M | +15.8% |
| 2024 | $30.64M | -7.2% |
| 2023 | $33.01M | -9.6% |
| 2022 | $36.49M | -29.4% |
| 2021 | $51.68M | +92.6% |
| 2020 | $26.84M | -32.8% |
| 2019 | $39.94M | -5.1% |
| 2018 | $42.11M | -0.4% |
| 2017 | $42.28M | -30.5% |
| 2016 | $60.86M | - |